Stochastic model of in-vivo X4 emergence during HIV infection implications for the CCR5 inhibitor maraviroc

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Savkovic, Borislav ^a   Symonds, Geoff ^b   Murray, John M ^a,c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b St Vincent's Centre for Applied Medical Research   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; MARAVIROC;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; DRUG EFFICACY; DRUG SAFETY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS X4 STRAIN; IN VIVO STUDY; MONOTHERAPY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION; STOCHASTIC MODEL; T LYMPHOCYTE ACTIVATION; TARGET CELL; VIRAL TROPISM; VIRUS MUTATION; VIRUS STRAIN;

CD4-POSITIVE T-LYMPHOCYTES; CYCLOHEXANES; HIV INFECTIONS; HUMANS; MODELS, THEORETICAL; RECEPTORS, CCR5; TRIAZOLES;

EID: 84863995591     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038755     Document Type: Article

References (72)

1. Westby M, van der Ryst E, (2010) CCR5 antagonists hosttargeted antiviral agents for the treatment of HIV infection, 4 years on. Antivir Chem Chemother 20: 179-192.
2. Agrawal L, Lu X, Qingwen J, VanHornAli Z, Nicolescu IV, et al. (2004) Role for CCR5Delta32 protein in resistance to R5, R5X4, and X4 human immunodeficiency virus type 1 in primary CD4 cells. J Virol 78: 2277-2287.
3. Alkhatib G, (2009) The biology of CCR5 and CXCR4. Curr Opin HIV AIDS 4: 96-103.
4. Corbeau P, Reynes J, (2009) CCR5 antagonism in HIV infection ways, effects, and side effects. AIDS 23: 1931-1943.
5. de Silva E, Stumpf MP, (2004) HIV and the CCR5Delta32 resistance allele. FEMS Microbiol Lett 241: 1-12.
6. Allers K, Hutter G, Hofmann J, Loddenkemper C, Rieger K, et al. (2011) Evidence for the cure of HIV infection by CCR5Delta32Delta32 stem cell transplantation. Blood 117: 2791-2799.
7. Doitsh G, Cavrois M, Lassen KG, Zepeda O, Yang Z, et al. (2010) Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. Cell 143: 789-801.
8. TroiaCancio P, Asmuth DM, (2011) Lessons from maraviroc clinical trials. Expert Rev Anti Infect Ther 9: 649-651.
9. PoizotMartin I, (2010) CCR5antagonists contribution of a new antiretroviral class to the management of HIV infection. Med Mal Infect 40: 245-255.
10. Kromdijk W, Huitema AD, Mulder JW, (2010) Treatment of HIV infection with the CCR5 antagonist maraviroc. Expert Opin Pharmacother 11: 1215-1223.
11. Fatkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, et al. (2008) Subgroup analyses of maraviroc in previously treated R5 HIV1 infection. N Engl J Med 359: 1442-1455.
12. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, et al. (2008) Maraviroc for previously treated patients with R5 HIV1 infection. N Engl J Med 359: 1429-1441.
13. Koot M, Keet IP, Vos AH, de Goede RE, Roos MT, et al. (1993) Prognostic value of HIV1 syncytiuminducing phenotype for rate of CD4 cell depletion and progression to AIDS. Ann Intern Med 118: 681-688.
14. Nishimura Y, Brown CR, Mattapallil JJ, Igarashi T, BucklerWhite A, et al. (2005) Resting naive CD4 T cells are massively infected and eliminated by X4tropic simianhuman immunodeficiency viruses in macaques. Proc Natl Acad Sci U S A 102: 8000-8005.
15. Shepherd JC, Jacobson LP, Qiao W, Jamieson BD, Phair JP, et al. (2008) Emergence and persistence of CXCR4tropic HIV1 in a population of men from the multicenter AIDS cohort study. J Infect Dis 198: 1104-1112.
16. Hazenberg MD, Otto SA, Hamann D, Roos MT, Schuitemaker H, et al. (2003) Depletion of naive CD4 T cells by CXCR4using HIV1 variants occurs mainly through increased Tcell death and activation. AIDS 17: 1419-1424.
17. Jekle A, Keppler OT, de Clercq E, Schols D, Weinstein M, et al. (2003) In vivo evolution of human immunodeficiency virus type 1 toward increased pathogenicity through CXCR4mediated killing of uninfected CD4 T cells. J Virol 77: 5846-5854.
18. Wolinsky SM, Veazey RS, Kunstman KJ, Klasse PJ, Dufour J, et al. (2004) Effect of a CCR5 inhibitor on viral loads in macaques dualinfected with R5 and X4 primate immunodeficiency viruses. Virology 328: 19-29.
19. Lewis M, Simpson P, Fransen S, Huang W, Whitcomb J, et al. (2007) CXCR4using virus detected in patients receiving maraviroc in the phase III studies MOTIVATE 1 and 2 originates from a preexisting minority of CXCR4using virus. Antiviral Therapy 200712 S65 Abstract 56.
20. Chalmet K, Dauwe K, Foquet L, Baatz F, SeguinDevaux C, et al. (2012) Presence of CXCR4using HIV1 in patients with recently diagnosed infection correlates and evidence for transmission. J Infect Dis 205: 174-184.
21. Ribeiro RM, Hazenberg MD, Perelson AS, Davenport MP, (2006) Naive and memory cell turnover as drivers of CCR5toCXCR4 tropism switch in human immunodeficiency virus type 1 implications for therapy. J Virol 80: 802-809.
22. Lee B, Sharron M, Montaner LJ, Weissman D, Doms RW, (1999) Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocytederived macrophages. Proc Natl Acad Sci U S A 96: 5215-5220.
23. Weinberger AD, Perelson AS, (2011) Persistence and emergence of X4 virus in HIV infection. Math Biosci Eng 8: 605-626.
24. Weinberger AD, Perelson AS, Ribeiro RM, Weinberger LS, (2009) Accelerated immunodeficiency by antiCCR5 treatment in HIV infection. PLoS Comput Biol 5: e1000467.
25. Davenport MP, Zaunders JJ, Hazenberg MD, Schuitemaker H, van Rij RP, (2002) Cell turnover and cell tropism in HIV1 infection. Trends Microbiol 10: 275-278.
26. Mansky LM, Temin HM, (1995) Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 69: 5087-5094.
27. Bozek K, Thielen A, Sierra S, Kaiser R, Lengauer T, (2009) V3 loop sequence space analysis suggests different evolutionary patterns of CCR5 and CXCR4tropic HIV. PLoS One 4: e7387.
28. de Jong JJ, de Ronde A, Keulen W, Tersmette M, Goudsmit J, (1992) Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytiuminducing phenotype analysis by single amino acid substitution. J Virol 66: 6777-6780.
29. Del Prete GQ, Leslie GJ, Haggarty B, Jordan AP, Romano J, et al. (2010) Distinct molecular pathways to X4 tropism for a V3truncated human immunodeficiency virus type 1 lead to differential coreceptor interactions and sensitivity to a CXCR4 antagonist. J Virol 84: 8777-8789.
30. Garrido C, Roulet V, Chueca N, Poveda E, Aguilera A, et al. (2008) Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes. J Clin Microbiol 46: 887-891.
31. Lengauer T, Sander O, Sierra S, Thielen A, Kaiser R, (2007) Bioinformatics prediction of HIV coreceptor usage. Nat Biotechnol 25: 1407-1410.
32. Tasca S, Ho SH, ChengMayer C, (2008) R5X4 viruses are evolutionary, functional, and antigenic intermediates in the pathway of a simianhuman immunodeficiency virus coreceptor switch. J Virol 82: 7089-7099.
33. Li Q, Duan L, Estes JD, Ma ZM, Rourke T, et al. (2005) Peak SIV replication in resting memory CD4 T cells depletes gut lamina propria CD4 T cells. Nature 434: 1148-1152.
34. Zhang ZQ, Wietgrefe SW, Li Q, Shore MD, Duan L, et al. (2004) Roles of substrate availability and infection of resting and activated CD4 T cells in transmission and acute simian immunodeficiency virus infection. Proc Natl Acad Sci U S A 101: 5640-5645.
35. Lee S, Lapham CK, Chen H, King L, Manischewitz J, et al. (2000) Coreceptor competition for association with CD4 may change the susceptibility of human cells to infection with Ttropic and macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 74: 5016-5023.
36. Murray JM, Fanning GC, Macpherson JL, Evans LA, Pond SM, et al. (2009) Mathematical modelling of the impact of haematopoietic stem celldelivered gene therapy for HIV. J Gene Med 11: 1077-1086.
37. Murray JM, Kaufmann GR, Hodgkin PD, Lewin SR, Kelleher AD, et al. (2003) Naive T cells are maintained by thymic output in early ages but by proliferation without phenotypic change after age twenty. Immunol Cell Biol 81: 487-495.
38. Bonyhadi ML, Rabin L, Salimi S, Brown DA, Kosek J, et al. (1993) HIV induces thymus depletion in vivo. Nature 363: 728-732.
39. Deeks SG, Kitchen CM, Liu L, Guo H, Gascon R, et al. (2004) Immune activation set point during early HIV infection predicts subsequent CD4 Tcell changes independent of viral load. Blood 104: 942-947.
40. Murray JM, Kaufmann G, Kelleher AD, Cooper DA, (1998) A model of primary HIV1 infection. Math Biosci 154: 57-85.
41. Essunger P, Perelson AS, (1994) Modeling HIV infection of CD4 Tcell subpopulations. J Theor Biol 170: 367-391.
42. Tebit DM, Nankya I, Arts EJ, Gao Y, (2007) HIV diversity, recombination and disease progression how does fitness fit into the puzzle AIDS Rev 9: 75-87.
43. Troyer RM, Collins KR, Abraha A, Fraundorf E, Moore DM, et al. (2005) Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression. J Virol 79: 9006-9018.
44. Frost SD, MartinezPicado J, Ruiz L, Clotet B, Brown AJ, (2002) Viral dynamics during structured treatment interruptions of chronic human immunodeficiency virus type 1 infection. J Virol 76: 968-979.
45. Garcia F, Plana M, Vidal C, Cruceta A, OBrien WA, et al. (1999) Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS 13: F79-86.
46. Lewin SR, Murray JM, Solomon A, Wightman F, Cameron PU, et al. (2008) Virologic determinants of success after structured treatment interruptions of antiretrovirals in acute HIV1 infection. J Acquir Immune Defic Syndr 47: 140-147.
47. Ribeiro RM, Bonhoeffer S, (1999) A stochastic model for primary HIV infection optimal timing of therapy. AIDS 13: 351-357.
48. Murray JM, McBride K, Boesecke C, Bailey M, Amin J, et al. (2012) Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards. AIDS 26: 543-550.
49. Huenecke S, Behl M, Fadler C, Zimmermann SY, Bochennek K, et al. (2008) Agematched lymphocyte subpopulation reference values in childhood and adolescence application of exponential regression analysis. Eur J Haematol 80: 532-539.
50. Pantaleo G, Graziosi C, Fauci AS, (1993) New concepts in the immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 328: 327-335.
51. Symons J, van Lelyveld SF, Hoepelman AI, van Ham PM, de Jong D, et al. (2011) Maraviroc is able to inhibit dualR5 viruses in a dualmixed HIV1infected patient. J Antimicrob Chemother 66: 890-895.
52. Zaunders J, Carr A, McNally L, Penny R, Cooper DA, (1995) Effects of primary HIV1 infection on subsets of CD4 and CD8 T lymphocytes. AIDS 9: 561-566.
53. Tilton JC, AmrineMadsen H, Miamidian JL, Kitrinos KM, Pfaff J, et al. (2010) HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drugbound receptor for entry. AIDS Res Hum Retroviruses 26: 13-24.
54. Trkola A, Kuhmann SE, Strizki JM, Maxwell E, Ketas T, et al. (2002) HIV1 escape from a small molecule, CCR5specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci U S A 99: 395-400.
55. Pastore C, Nedellec R, Ramos A, Pontow S, Ratner L, et al. (2006) Human immunodeficiency virus type 1 coreceptor switching V1V2 gainoffitness mutations compensate for V3 lossoffitness mutations. J Virol 80: 750-758.
56. Shakirzyanova M, Ren W, Zhuang K, Tasca S, ChengMayer C, (2010) Fitness disadvantage of transitional intermediates contributes to dynamic change in the infectingvirus population during coreceptor switch in R5 simianhuman immunodeficiency virusinfected macaques. J Virol 84: 12862-12871.
57. Svicher V, Balestra E, Cento V, Sarmati L, Dori L, et al. (2011) HIV1 dualmixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro. Antiviral Res 90: 42-53.
58. Regoes RR, Bonhoeffer S, (2005) The HIV coreceptor switch a population dynamical perspective. Trends Microbiol 13: 269-277.
59. Igarashi T, Brown CR, Byrum RA, Nishimura Y, Endo Y, et al. (2002) Rapid and irreversible CD4 Tcell depletion induced by the highly pathogenic simianhuman immunodeficiency virus SHIVDH12R is systemic and synchronous. J Virol 76: 379-391.
60. Igarashi T, Brown CR, Endo Y, BucklerWhite A, Plishka R, et al. (2001) Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4 T cells by a highly pathogenic simian immunodeficiency virusHIV type 1 chimera SHIV Implications for HIV1 infections of humans. Proc Natl Acad Sci U S A 98: 658-663.
61. Lewin SR, Sonza S, Irving LB, McDonald CF, Mills J, et al. (1996) Surface CD4 is critical to in vitro HIV infection of human alveolar macrophages. AIDS Res Hum Retroviruses 12: 877-883.
62. Tokunaga K, Greenberg ML, Morse MA, Cumming RI, Lyerly HK, et al. (2001) Molecular basis for cell tropism of CXCR4dependent human immunodeficiency virus type 1 isolates. J Virol 75: 6776-6785.
63. Ren W, Tasca S, Zhuang K, Gettie A, Blanchard J, et al. (2010) Different tempo and anatomic location of dualtropic and X4 virus emergence in a model of R5 simianhuman immunodeficiency virus infection. J Virol 84: 340-351.
64. Carter CC, McNamara LA, OnafuwaNuga A, Shackleton M, Riddell Jt, et al. (2011) HIV1 utilizes the CXCR4 chemokine receptor to infect multipotent hematopoietic stem and progenitor cells. Cell Host Microbe 9: 223-234.
65. Nazari R, Ma XZ, Joshi S, (2008) Inhibition of human immunodeficiency virus1 entry using vectors expressing a multimeric hammerhead ribozyme targeting the CCR5 mRNA. J Gen Virol 89: 2252-2261.
66. Nazari R, Joshi S, (2008) CCR5 as target for HIV1 gene therapy. Curr Gene Ther 8: 264-272.
67. McLean AR, Michie CA, (1995) In vivo estimates of division and death rates of human T lymphocytes. Proc Natl Acad Sci U S A 92: 3707-3711.
68. Ahmed R, Gray D, (1996) Immunological memory and protective immunity understanding their relation. Science 272: 54-60.
69. Klein J, (1990) Immunology. Blackwell Scientific Boston.
70. Notermans DW, Pakker NG, Hamann D, Foudraine NA, Kauffmann RH, et al. (1999) Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1infected adults. J Infect Dis 180: 1050-1056.
71. Haase AT, Henry K, Zupancic M, Sedgewick G, Faust RA, et al. (1996) Quantitative image analysis of HIV1 infection in lymphoid tissue. Science 274: 985-989.
72. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD, (1996) HIV1 dynamics in vivo virion clearance rate, infected cell lifespan, and viral generation time. Science 271: 1582-1586.